We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$385M
AUM Growth
-$76.2M
Cap. Flow
+$14.6M
Cap. Flow %
3.8%
Top 10 Hldgs %
44.6%
Holding
124
New
35
Increased
20
Reduced
21
Closed
33

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$16.8M
2
LLY icon
Eli Lilly
LLY
+$15.1M
3
SHPG
Shire pic
SHPG
+$13.7M
4
AMGN icon
Amgen
AMGN
+$13.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.79M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.6M
2
BIIB icon
Biogen
BIIB
+$18M
3
ORA icon
Ormat Technologies
ORA
+$13.3M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$6.65M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.41M

Sector Composition

Rank Sector Weight
1 Healthcare 83.18%
2 Miscellaneous 8.54%
3 Technology 4.38%
4 Communication Services 1.71%
5 Consumer Discretionary 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
101
Heron Therapeutics
HRTX
$59.9M
– –
-100,000
Closed -$1.9M
ICL icon
102
ICL Group
ICL
$7.15B
– –
-437,671
Closed -$1.9M
IONS icon
103
Ionis Pharmaceuticals
IONS
$7.74B
– –
-40,000
Closed -$1.62M
MNKD icon
104
CALL
MannKind Corp
MNKD
$1.14B
– –
-92,720
Closed -$746K
NBIX icon
105
Neurocrine Biosciences
NBIX
$15.3B
– –
-70,000
Closed -$2.77M
NICE icon
106
Nice
NICE
$6.23B
– –
-27,300
Closed -$1.77M
ORA icon
107
Ormat Technologies
ORA
$5.97B
– –
-322,193
Closed -$13.3M
PANW icon
108
Palo Alto Networks
PANW
$308B
– –
-103,050
Closed -$2.8M
VNDA icon
109
Vanda Pharmaceuticals
VNDA
$306M
– –
-512,051
Closed -$4.28M
WAB icon
110
Wabtec
WAB
$47.4B
– –
-21,704
Closed -$1.72M
XLF icon
111
PUT
State Street Financial Select Sector SPDR ETF
XLF
$53.5B
– –
-227,829
Closed -$4.5M
XLV icon
112
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.8B
– –
-750,000
Closed -$50.8M
ZVRA icon
113
Zevra Therapeutics
ZVRA
$705M
– –
-11,497
Closed -$2.67M
ALPN
114
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-19,975
Closed -$333K
PTNR
115
DELISTED
Partner Communications
PTNR
– –
-624,230
Closed -$2.91M
SBBP
116
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-60,718
Closed -$277K
CHMA
117
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-230,649
Closed -$2.11M
PTLA
118
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-80,100
Closed -$1.63M
PTLA
119
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-50,000
Closed -$1.02M
MLNX
120
DELISTED
Mellanox Technologies, Ltd.
MLNX
– –
-36,760
Closed -$2M
IGLD
121
DELISTED
Internet Gold-Golden Lines Ltd
IGLD
– –
-503
Closed -$678K
OCRX
122
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-186,800
Closed -$549K
TBRA
123
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-32,300
Closed -$264K
RPTP
124
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-400,000
Closed -$1.84M
1 2 3 4
5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sphera Funds Management held 124 positions worth $385M, down 17% from $461M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $14.6M of net new capital in Q2 2016, opening 35 new positions and adding to 20 existing holdings. Its largest new stake was GSK: 318,630 shares worth $6.39M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 67% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Pfizer, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q2 2016 buy was GSK: 318,630 shares worth $6.39M.
  • Sphera Funds Management added most to Shire pic in Q2 2016, an estimated $13.7M increase.
  • Sphera Funds Management's biggest Q2 2016 reduction was Pfizer, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited Ormat Technologies in Q2 2016, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $385M portfolio in Q2 2016.
  • Sphera Funds Management opened 35 new positions and closed 33 in Q2 2016.
  • Sphera Funds Management's portfolio value fell 17% quarter-over-quarter to $385M.

Based on Sphera Funds Management's 13F filing for Q2 2016, filed 10 Aug 2016.